Repeated CBD Administration and Cannabis Outcomes

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorHannah Harris

About this trial

This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.

Eligibility criteria

Qualifiers

English-speaking, literate adults,

Male or female,

Between the ages of 18-55,

Body Mass Index from 18.5-32.0 kg/m2,

Disqualifiers

Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,

Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders [e.g., asthma, COPD]),

Current or past history of major psychiatric disorder that would limit ability to participate in the study,

Use of cannabis exclusively for medical reasons (no recreational use reported),

Trial design

Treatments tested in this trial

  • Cannabidiol, Medium Dose
  • Cannabidiol, Higher Dose
  • Active Inhaled Cannabis
  • Placebo Cannabidiol
  • Placebo Inhaled Cannabis

Treatment groups

23 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Sponsors and collaborators

Hannah Harris

Lead sponsor

University of Kentucky

Sponsor institution

National Institute on Drug Abuse (NIDA)

Collaborator